Phase II Study of Axitinib (AG-013736) with Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
Study of Experimental Drug (Axitinib) in Patients with Metastatic Pheochromocytoma (PCC) or Paraganglioma
Sponsor: Pfizer
Enrolling: Male and Female Patients
IRB Number: AAAR5314
U.S. Govt. ID: NCT03839498
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: Axitinib (AG-013736) is an investigational (experimental) drug that is being studied in patients with metastatic pheochromocytoma/paraganglioma. The main goal of this study is to find out if axitinib is able to stop tumors from growing, or shrink tumors in patients with this type of cancer.
This study is closed
Investigator
Antonio Fojo, MD, PhD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with pheochromocytoma or paraganglioma? Yes No
Do you have a life expectancy of at least 3 months? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE